Development Proposal-Based Contract Manufacturing Built on Joint Development

「Through these operations, we will work to further expand the business by increasing production of prefilled syringe products, for which needs are high at medical institutions, and securing new contract manufacturing projects currently under consideration.」

「Sustainable growth through an ESG-conscious, development-oriented contract business (CDMO (Note 5)) covering development through manufacturing」

「Through this construction project, we aim to further expand the business by increasing production of prefilled syringe products, for which demand is high at pharmaceutical manufacturing sites, and securing new contract projects currently under consideration.」

「We will promote a development-oriented CDMO structure covering the process from pharmaceutical development through manufacturing. To fully develop the contract business at the Zao Plant, we will work over the medium term to secure new contracts for vial liquid formulations and lyophilized products and increase production of syringe products (Note 5).」

「Among the main contract-manufacturing products, injectable drugs for which preparations to increase production had been under way performed steadily, owing in part to a further increase in production from January this year and higher sales volumes.」

「In the pharmaceutical manufacturing and sales business, the main contract-manufactured injectable products for which the company had been establishing a higher production capacity performed well, supported by increased volumes resulting from growth in the products' generic drug market share and other factors. Existing products also performed well due to replacement demand arising from the discontinuation of some products by competitors and other factors, resulting in sales of ¥4,372 million, up 9.5% year on year, for the six months ended the second quarter.」

「In the pharmaceutical manufacturing and sales business, the main contract-manufactured injectable products for which the company had been establishing a higher production capacity performed well, supported by increased volumes resulting from growth in the products' generic drug market share and other factors. Existing contract-manufactured products also performed well, and replacement demand arose after some products of competitors were discontinued. As a result, sales were ¥2,230 million, up 17.8% year on year.」

「In the pharmaceutical manufacturing and sales business, among the main contract-manufactured products, injectable products for which the company had been establishing a higher production capacity performed well, reflecting increased volumes resulting from growth in the products' generic drug market share and revisions to selling prices. Sales for the nine months ended the third quarter were ¥5,983 million, up 6.4% year on year. Despite higher costs for raw materials, utilities and other items due to the weaker yen and soaring fuel prices, segment profit increased with sales and the company worked to secure profit through productivity improvements from higher production and improved yields, resulting in segment profit of ¥1,234 million, up 0.7% year on year.」

「In the pharmaceutical manufacturing and sales business, the main contract-manufactured products performed well against a backdrop of expanding generic drug market share and progress in establishing a higher production capacity, resulting in sales of ¥3,994 million for the fiscal year, up 2.7% year on year.」

「In the pharmaceutical manufacturing and sales business, the main contract-manufactured products performed well as their share of the generic drug market expanded, resulting in sales of ¥1,892 million, up 8.3% year on year, and segment profit of ¥337 million, up 28.5% year on year.」

「In the pharmaceutical manufacturing and sales business, contract manufacturing remained strong, resulting in sales of ¥5,623 million, up 10.8% year on year, and segment profit of ¥1,224 million, up 39.8% year on year, for the nine months ended the third quarter.」

「In the pharmaceutical manufacturing and sales business, contract manufacturing remained strong, resulting in sales of ¥3,888 million, up 18.9% year on year, and segment profit of ¥862 million, up 78.0% year on year, for the six months ended the second quarter.」

「In the pharmaceutical manufacturing and sales business, contract manufacturing remained strong, resulting in sales of ¥1,748 million, up 16.6% year on year, and segment profit of ¥262 million, up 71.1% year on year.」

「In the pharmaceutical manufacturing and sales business, contract manufacturing remained strong throughout the year, resulting in sales of ¥7,021 million, up 22.8% year on year, and segment profit of ¥1,199 million, up 165.0% year on year.」

「In the pharmaceutical manufacturing and sales business, contract manufacturing remained strong, resulting in sales of ¥5,072 million, up 27.9% year on year, and segment profit of ¥876 million, up 281.1% year on year, for the nine months ended the third quarter.」

「In the pharmaceutical manufacturing and sales business, contract manufacturing remained strong, resulting in sales of ¥3,271 million, up 30.8% year on year, and segment profit of ¥484 million, up 668.6% year on year, for the six months ended the second quarter.」

「In the pharmaceutical manufacturing and sales business, contract manufacturing remained strong, with sales of ¥1,500 million, up 72.6% year on year, and segment profit of ¥153 million, compared with a loss of ¥136 million in the same period of the previous year.」

「In the pharmaceutical manufacturing and sales business, the start of contract manufacturing for certain products contributed to sales, which were ¥2,501 million, up 24.0% year on year, while segment profit was ¥63 million, compared with a segment loss of ¥251 million in the same period of the previous year.」

「The company also manufactures and sells internally developed products and undertakes contract manufacturing for major domestic manufacturers and others, thereby operating a business capable of meeting diverse needs in the pharmaceutical industry, primarily for generic drugs.」

「The company also manufactures and sells internally developed products and undertakes contract manufacturing for major domestic manufacturers and others, thereby operating a business capable of meeting diverse needs in the pharmaceutical industry, primarily for generic drugs.」

「The company also manufactures and sells internally developed products and products jointly developed with other pharmaceutical manufacturers, and undertakes contract manufacturing for major domestic manufacturers and others, thereby operating a business capable of meeting diverse needs in the pharmaceutical industry, primarily for generic drugs.」

「The company also manufactures and sells internally developed products and products jointly developed with other pharmaceutical manufacturers, and undertakes contract manufacturing for major domestic manufacturers and others, thereby operating a business capable of meeting diverse needs in the pharmaceutical industry, primarily for generic drugs.」

「We intend to promote a development-oriented contract manufacturing business that handles the entire process, from research and development through contract manufacturing, in-house.」